AU2011225095C1 - N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof - Google Patents

N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof Download PDF

Info

Publication number
AU2011225095C1
AU2011225095C1 AU2011225095A AU2011225095A AU2011225095C1 AU 2011225095 C1 AU2011225095 C1 AU 2011225095C1 AU 2011225095 A AU2011225095 A AU 2011225095A AU 2011225095 A AU2011225095 A AU 2011225095A AU 2011225095 C1 AU2011225095 C1 AU 2011225095C1
Authority
AU
Australia
Prior art keywords
optionally substituted
alkyl
group
halogen
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011225095A
Other languages
English (en)
Other versions
AU2011225095B2 (en
AU2011225095A1 (en
Inventor
Keisuke Kakiguchi
Naoya Kinomura
Megumi Maruyama
Satoshi Nojima
Masahiro Takamura
Hiroto Tatamidani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of AU2011225095A1 publication Critical patent/AU2011225095A1/en
Assigned to SUMITOMO DAINIPPON PHARMA CO., LTD. reassignment SUMITOMO DAINIPPON PHARMA CO., LTD. Alteration of Name(s) of Applicant(s) under S113 Assignors: DAINIPPON SUMITOMO PHARMA CO., LTD.
Publication of AU2011225095B2 publication Critical patent/AU2011225095B2/en
Application granted granted Critical
Publication of AU2011225095C1 publication Critical patent/AU2011225095C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2011225095A 2010-03-11 2011-03-11 N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof Ceased AU2011225095C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010-054177 2010-03-11
JP2010054177 2010-03-11
JP2010-285844 2010-12-22
JP2010285844 2010-12-22
PCT/JP2011/056497 WO2011111875A1 (en) 2010-03-11 2011-03-11 N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof

Publications (3)

Publication Number Publication Date
AU2011225095A1 AU2011225095A1 (en) 2012-09-27
AU2011225095B2 AU2011225095B2 (en) 2016-05-19
AU2011225095C1 true AU2011225095C1 (en) 2017-01-19

Family

ID=44563664

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011225095A Ceased AU2011225095C1 (en) 2010-03-11 2011-03-11 N-Acyl cyclic amine derivative or pharmaceutically acceptable salt thereof

Country Status (9)

Country Link
US (1) US8541585B2 (cg-RX-API-DMAC7.html)
EP (1) EP2545046A4 (cg-RX-API-DMAC7.html)
JP (1) JP5661791B2 (cg-RX-API-DMAC7.html)
KR (1) KR101756495B1 (cg-RX-API-DMAC7.html)
CN (1) CN102884059B (cg-RX-API-DMAC7.html)
AU (1) AU2011225095C1 (cg-RX-API-DMAC7.html)
CA (1) CA2792539C (cg-RX-API-DMAC7.html)
TW (1) TWI475015B (cg-RX-API-DMAC7.html)
WO (1) WO2011111875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180872B (zh) * 2011-04-01 2014-04-02 华中科技大学 [1,3,4]噁二唑类衍生物及其应用
CN104892589A (zh) * 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
PL245933B1 (pl) 2014-07-04 2024-11-04 Inst Farmakologii Polskiej Akademii Nauk (Chinolino lub izochinolino) sulfonamidy amin cyklicznych, kompozycja je zawierająca, sposób ich wytwarzania oraz ich zastosowanie medyczne
CN105315267B (zh) * 2014-07-30 2019-06-04 江苏恩华药业股份有限公司 一种酰胺类衍生物及其应用
JP2019059672A (ja) * 2015-12-28 2019-04-18 大日本住友製薬株式会社 治療抵抗性うつ病等の治療薬
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
JP7655885B2 (ja) * 2021-06-30 2025-04-02 住友ファーマ株式会社 脂肪族酸アミド誘導体を含有する医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133061A (en) 1962-11-13 1964-05-12 Sterling Drug Inc Piperidine carboxamides and derivatives thereof
FR2285883A1 (fr) 1974-09-30 1976-04-23 Cerm Cent Europ Rech Mauvernay Nouveaux composes chimiques a activite bronchospasmolytique et antitussive, et procede pour leur obtention
JPH08502474A (ja) * 1992-10-07 1996-03-19 メルク エンド カンパニー インコーポレーテッド トコリティックオキシトシンレセプターアンタゴニスト
JP3162572B2 (ja) 1993-04-28 2001-05-08 住友製薬株式会社 インドロイルグアニジン誘導体
JPH08208602A (ja) 1994-10-18 1996-08-13 Sumitomo Pharmaceut Co Ltd インドロイルグアニジン誘導体
FR2729954B1 (fr) 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
US6166037A (en) * 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
UA58476C2 (uk) 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
US7164024B2 (en) 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
FR2824828B1 (fr) * 2001-05-21 2005-05-20 Sanofi Synthelabo Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
AU2002351733A1 (en) 2001-12-19 2003-06-30 H. Lundbeck A/S 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
MXPA06007654A (es) * 2003-12-31 2006-09-04 Warner Lambert Co Derivados de piperidina n-sustituidos.
WO2006033943A2 (en) 2004-09-17 2006-03-30 Exelixis, Inc Pyrazole kinase modulators and methods of use
WO2007061741A2 (en) 2005-11-17 2007-05-31 Arena Pharmaceuticals, Inc. Modulators of the h3 receptor useful for the treatment of disorders related thereto
JP5176281B2 (ja) 2006-03-23 2013-04-03 大日本印刷株式会社 リチウムイオン電池

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861417A (en) * 1996-12-19 1999-01-19 Hoechst Marion Roussel, Inc. Heterocyclic substituted pyrrolidine amide derivatives

Also Published As

Publication number Publication date
KR20130016234A (ko) 2013-02-14
US20120214790A1 (en) 2012-08-23
CA2792539C (en) 2017-04-18
JP2013522165A (ja) 2013-06-13
AU2011225095B2 (en) 2016-05-19
CN102884059B (zh) 2015-08-26
EP2545046A4 (en) 2015-03-25
TWI475015B (zh) 2015-03-01
WO2011111875A1 (en) 2011-09-15
EP2545046A1 (en) 2013-01-16
AU2011225095A1 (en) 2012-09-27
US8541585B2 (en) 2013-09-24
TW201139413A (en) 2011-11-16
KR101756495B1 (ko) 2017-07-10
JP5661791B2 (ja) 2015-01-28
CA2792539A1 (en) 2011-09-15
CN102884059A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
US9452997B2 (en) Piperidine and piperazine derivatives as autotaxin inhibitors
AU2004281215B2 (en) Derivatives of N-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
US8541585B2 (en) N-acyl cyclic amine derivative or pharmaceutically acceptable salt thereof
US20220289746A1 (en) Pyrrolidine derivatives
TW201311674A (zh) 吲唑－及吡咯并吡啶－衍生物及其醫藥用途
CN102686580A (zh) 用作酪蛋白激酶抑制剂的咪唑衍生物
TW200904433A (en) Substituted imidazole compound and use thereof
JP5715605B2 (ja) Ｎ−アシル環状アミン誘導体またはその医薬上許容される塩からなる医薬
JP2014506905A (ja) 新規なベンゾジオキソールピペリジン化合物
JP5677457B2 (ja) ピロリジン誘導体
JP5410536B2 (ja) ３−（ベンジルアミノ）−ピロリジン誘導体及びｎｋ−３受容体アンタゴニストとしてのその使用
CN102656157B (zh) 作为nk-3受体拮抗剂的吡咯烷衍生物
US20080221116A1 (en) ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS
US8318749B2 (en) Quinazoline derivatives as NK3 receptor antagonists
WO2004000837A1 (ja) 新規なベンズオキサゾリノン誘導体
CN101243075A (zh) 新颖的2,3-二氢吲哚化合物
JP2010529068A (ja) Ｎｋ３受容体アンタゴニストとしてのプロリンアミド−テトラゾール誘導体

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 MAY 2016 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 31 MAY 2016

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 SEP 2016

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MARUYAMA, MEGUMI; KINOMURA, NAOYA; NOJIMA, SATOSHI; TAKAMURA, MASAHIRO; KAKIGUCHI, KEISUKE AND TATAMIDANI, HIROTO

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MARUYAMA, MEGUMI; KINOMURA, NAOYA; NOJIMA, SATOSHI; TAKAMURA, MASAHIRO; KAKIGUCHI, KEISUKE AND TATAMIDANI, HIROTO

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 SEP 2016

MK14 Patent ceased section 143(a) (annual fees not paid) or expired